(Hypertension. 1997;30:1015-1019.)
© 1997 American Heart Association, Inc.
Articles |
High Plasma Level of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline
A New Marker of Chronic Angiotensin-Converting Enzyme Inhibition
From the Broussais Hospital Clinical Investigation Center, INSERM, and Assistance Publique des Hôpitaux de Paris (M.A., L.N., J.M.), and the Service de Pharmacologie et d'Immunologie, CEA, Gif-sur-Yvette (E.E., J.-M.G.), France.
Abstract The acute administration of the angiotensin-converting enzyme (ACE) inhibitor captopril to healthy subjects transiently increases 5.5-fold the plasma levels of a natural stem-cell regulator, N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP). The aim of this study was to measure plasma Ac-SDKP levels during chronic treatment with all types of ACE inhibitors and to assess its relevance as a marker of ACE inhibition. Plasma levels of Ac-SDKP were blindly determined in age- and sex-matched hypertensive patients either treated (ACEI group, n=27) or not (non-ACEI group, n=23) with an ACE inhibitor for more than 1 month. Geometric mean [range] of plasma Ac-SDKP levels were significantly higher in the ACEI group (3.78 [1.48 to 14.5] pmol/mL) than in the non-ACEI group, with no overlap between the groups (0.75 [0.36 to 1.22] pmol/mL, P<.0001). The measurement of Ac-SDKP in plasma discriminated all the patients of the ACEI group, whereas the simultaneous determination of either in vitro (using hippuryl-histidine-leucine as substrate) or in vivo (angiotensin II/angiotensin I ratio) ACE activity failed to identify nine and five cases, respectively. We conclude that Ac-SDKP accumulates in plasma during chronic ACE inhibitor treatment. The long-term consequences of Ac-SDKP accumulation are unknown. The reliability of plasma Ac-SDKP measurement makes it the best marker of chronic ACE inhibition, which can help to verify patients' compliance to ACE inhibitor treatment.
Key Words: peptides • angiotensin-converting enzyme inhibition • diagnosis • patient compliance
This article has been cited by other articles:
 |
|
 |
|
  E. Habouzit, H. Richard, H. Sanchez, N. Koulmann, B. Serrurier, R. Monnet, R. Ventura-Clapier, and X. Bigard Decreased muscle ACE activity enhances functional response to endurance training in rats, without change in muscle oxidative capacity or contractile phenotype J Appl Physiol, July 1, 2009; 107(1): 346 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-X. Lin, N.-E. Rhaleb, X.-P. Yang, T.-D. Liao, M. A. D'Ambrosio, and O. A. Carretero Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1253 - H1261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Lew, F. J. Warner, I. Hanchapola, M. A. Yarski, J. Manohar, L. M. Burrell, and A. I. Smith Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor Exp Physiol, May 1, 2008; 93(5): 685 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Sharma, N.-E. Rhaleb, S. Pokharel, P. Harding, S. Rasoul, H. Peng, and O. A. Carretero Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1226 - H1232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Cavasin, T.-D. Liao, X.-P. Yang, J. J. Yang, and O. A. Carretero Decreased Endogenous Levels of Ac-SDKP Promote Organ Fibrosis Hypertension, July 1, 2007; 50(1): 130 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Peng, O. A. Carretero, T.-D. Liao, E. L. Peterson, and N.-E. Rhaleb Role of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline in the Antifibrotic and Anti-Inflammatory Effects of the Angiotensin-Converting Enzyme Inhibitor Captopril in Hypertension Hypertension, March 1, 2007; 49(3): 695 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Paul, A. Poyan Mehr, and R. Kreutz Physiology of local Renin-Angiotensin systems. Physiol Rev, July 1, 2006; 86(3): 747 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Azizi, J. Menard, S. Peyrard, M. Lievre, M. Marre, and G. Chatellier Assessment of Patients' and Physicians' Compliance to an ACE Inhibitor Treatment Based on Urinary N-Acetyl Ser-Asp-Lys-Pro Determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) Study. Diabetes Care, June 1, 2006; 29(6): 1331 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Waeckel, J. Bignon, J.-M. Liu, D. Markovits, T. G. Ebrahimian, J. Vilar, B. Mees, O. Blanc-Brude, V. Barateau, S. Le ricousse-Roussanne, et al. Tetrapeptide AcSDKP Induces Postischemic Neovascularization Through Monocyte Chemoattractant Protein-1 Signaling Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 773 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Peng, O. A. Carretero, N. Vuljaj, T.-D. Liao, A. Motivala, E. L. Peterson, and N.-E. Rhaleb Angiotensin-Converting Enzyme Inhibitors: A New Mechanism of Action Circulation, October 18, 2005; 112(16): 2436 - 2445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Wang, O. A. Carretero, X.-Y. Yang, N.-E. Rhaleb, Y.-H. Liu, T.-D. Liao, and X.-P. Yang N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2099 - H2105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Charrier, A. Michaud, S. Badaoui, S. Giroux, E. Ezan, F. Sainteny, P. Corvol, and W. Vainchenker Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells Blood, August 15, 2004; 104(4): 978 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Cavasin, N.-E. Rhaleb, X.-P. Yang, and O. A. Carretero Prolyl Oligopeptidase Is Involved in Release of the Antifibrotic Peptide Ac-SDKP Hypertension, May 1, 2004; 43(5): 1140 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fuchs, H. D. Xiao, J. M. Cole, J. W. Adams, K. Frenzel, A. Michaud, H. Zhao, G. Keshelava, M. R. Capecchi, P. Corvol, et al. Role of the N-terminal Catalytic Domain of Angiotensin-converting Enzyme Investigated by Targeted Inactivation in Mice J. Biol. Chem., April 16, 2004; 279(16): 15946 - 15953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Peng, O. A. Carretero, D. R. Brigstock, N. Oja-Tebbe, and N.-E. Rhaleb Ac-SDKP Reverses Cardiac Fibrosis in Rats With Renovascular Hypertension Hypertension, December 1, 2003; 42(6): 1164 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Pokharel, S. Rasoul, A. J.M. Roks, R. E.W. van Leeuwen, M. J.A. van Luyn, L. E. Deelman, J. F. Smits, O. Carretero, W. H. van Gilst, and Y. M. Pinto N-Acetyl-Ser-Asp-Lys-Pro Inhibits Phosphorylation of Smad2 in Cardiac Fibroblasts Hypertension, August 1, 2002; 40(2): 155 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N.-E. Rhaleb, H. Peng, X.-P. Yang, Y.-H. Liu, D. Mehta, E. Ezan, and O. A. Carretero Long-Term Effect of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline on Left Ventricular Collagen Deposition in Rats With 2-Kidney, 1-Clip Hypertension Circulation, June 26, 2001; 103(25): 3136 - 3141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N.-E. Rhaleb, H. Peng, P. Harding, M. Tayeh, M. C. LaPointe, and O. A. Carretero Effect of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline on DNA and Collagen Synthesis in Rat Cardiac Fibroblasts Hypertension, March 1, 2001; 37(3): 827 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Peng, O. A. Carretero, M. E. Alfie, J. A. Masura, and N.-E. Rhaleb Effects of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Type 1 Receptor Antagonist in Deoxycorticosterone Acetate-Salt Hypertensive Mice Lacking Ren-2 Gene Hypertension, March 1, 2001; 37(3): 974 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Peng, O. A. Carretero, L. Raij, F. Yang, A. Kapke, and N.-E. Rhaleb Antifibrotic Effects of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline on the Heart and Kidney in Aldosterone-Salt Hypertensive Rats Hypertension, February 1, 2001; 37(2): 794 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Struthers, R. MacFadyen, C. Fraser, J. Robson, J. J. Morton, C. Junot, and E. Ezan Nonadherence with angiotensin-converting enzyme inhibitor therapy: A comparison of different ways of measuring it in patients with chronic heart failure J. Am. Coll. Cardiol., December 1, 1999; 34(7): 2072 - 2077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Junot, L. Nicolet, E. Ezan, M.-F. Gonzales, J. Menard, and M. Azizi Effect of Angiotensin-Converting Enzyme Inhibition on Plasma, Urine, and Tissue Concentrations of Hemoregulatory Peptide Acetyl-Ser-Asp-Lys-Pro in Rats J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 982 - 987. [Abstract] [Full Text]
|
|
|
|
 |
|
 A D Struthers, G Anderson, R J MacFadyen, C Fraser, and T M MacDonald Non-adherence with ACE inhibitor treatment is common in heart failure and can be detected by routine serum ACE activity assays Heart, November 1, 1999; 82(5): 584 - 588. [Abstract] [Full Text]
|
|
|
|
|
|
C. Junot, J. Menard, M.-F. Gonzales, A. Michaud, P. Corvol, and E. Ezan In Vivo Assessment of Captopril Selectivity of Angiotensin I-Converting Enzyme Inhibition: Differential Inhibition of Acetyl-Ser-Asp-Lys-Pro and Angiotensin I Hydrolysis J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1257 - 1261. [Abstract] [Full Text]
|
|
|
|
|
|
M. Azizi, E. Ezan, J.-L. Reny, J. Wdzieczak-Bakala, V. Gerineau, and J. Menard Renal and Metabolic Clearance of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (AcSDKP) During Angiotensin-Converting Enzyme Inhibition in Humans Hypertension, March 1, 1999; 33(3): 879 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Le Meur, J.-C. Aldigier, V. Praloran, M. Azizi, and E. Ezan Is Plasma Ac-SDKP Level a Reliable Marker of Chronic Angiotensin-Converting Enzyme Inhibition in Hypertensive Patients? • Response Hypertension, May 1, 1998; 31(5): 1201 - 1202. [Full Text] [PDF]
|
|